03/12/2025 Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera Read more about Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
02/28/2025 Ono Pharmaceutical Announces Reorganization of its US and Europe Operations Read more about Ono Pharmaceutical Announces Reorganization of its US and Europe Operations
02/14/2025 U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) Read more about U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
08/15/2024 U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) Read more about U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
07/19/2024 European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) Read more about European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
06/11/2024 Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) Read more about Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
06/03/2024 Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet Read more about Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
04/29/2024 Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion Read more about Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
04/09/2024 Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum Read more about Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
02/27/2024 Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences Read more about Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
